Oncolytic viruses, once considered medical curiosities, are now cutting-edge tools in the fight against some of the most challenging cancers, like glioblastoma. These tiny engineered viruses ...
Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that ...
Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunotherapy.
A new cancer therapy utilising a genetically modified herpes simplex virus type 1 (HSV-1) offers hope for late-stage patients ...
Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...
A progress report for a phase 1 trial of CLD-101 in recurrent glioma shows safety and feasibility at multiple intracerebral ...
RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback